Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
27 March 2000Website:
http://www.edwards.comNext earnings report:
06 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 37 min agoDividend
Analysts recommendations
Institutional Ownership
Included in screeners
EW Latest News
NEW YORK, Nov. 21, 2024 /PRNewswire/ -- The Gross Law Firm has an announcement for shareholders of Edwards Lifesciences Corporation (NYSE: EW). Those who bought shares of EW during the specified time are invited to reach out to the firm about the chance to be appointed as lead plaintiff.
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112912&wire=1 or reach out to Joseph E. Levi, Esq.
James (Josh) Wilson, a partner at Faruqi & Faruqi, LLP, is urging investors who lost over $100,000 in Edwards between February 6, 2024, and July 24, 2024, to reach out to him to explore their legal options. Interested individuals can contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Additionally, Faruqi & Faruqi is looking into possible claims against Edwards Lifesciences Corporation and reminds investors that the deadline to apply as lead plaintiff in a federal securities class action is December 13, 2024.
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112895&wire=1 or reach out to Joseph E. Levi, Esq.
On November 20, 2024, Bleichmar Fonti & Auld LLP, a prominent securities law firm, announced that a lawsuit has been initiated against Edwards Lifesciences Corporation (NYSE:EW) and some of its top executives for possible breaches of federal securities laws. If you have invested in Edwards Lifesciences, you are invited to find more details by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation.
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112875&wire=1 or reach out to Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / November 20, 2024 / The Schall Law Firm, a national firm focused on shareholder rights, is reminding investors about a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW). This lawsuit claims violations of the Securities Exchange Act of 1934 and related rules by the U.S. Securities and Exchange Commission. Investors who bought the Company's securities between February 6, 2024, and July 24, 2024, are urged to reach out to the firm before December 13, 2024.
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112870&wire=1 or reach out to Joseph E. Levi, Esq.
SAN DIEGO, Nov. 20, 2024 /PRNewswire/ -- The law firm Robbins Geller Rudman & Dowd LLP has announced that individuals who bought or acquired securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024, and July 24, 2024, have until Friday, December 13, 2024, to apply for the role of lead plaintiff in the class action lawsuit against Edwards Lifesciences. The case is titled Patel v.
Investors in Edwards Lifesciences Corporation (NYSE:EW) who have experienced significant losses are encouraged to report their losses. The class action lawsuit covers the period from February 6, 2024, to July 24, 2024, with a deadline for lead plaintiffs set for December 13, 2024. The case examines whether the company properly disclosed information regarding its main product, the Transcatheter Aortic Valve Replacement (TAVR) platform.
What type of business is Edwards Lifesciences?
Edwards Lifesciences Corporation is an American company headquartered in Irvine, California, specializing in the production and distribution of medical equipment for monitoring structural heart diseases and intensive therapy. It was founded in 1958. It is the world's leading manufacturer of cardiovascular system valves and means for their replacement or repair. It is also a global leader in the field of hemodynamic monitoring systems used to measure the cardiovascular function of patients. The company's products and solutions can be divided into several groups: transcatheter therapy, surgical therapy, intensive therapy.
What sector is Edwards Lifesciences in?
Edwards Lifesciences is in the Healthcare sector
What industry is Edwards Lifesciences in?
Edwards Lifesciences is in the Medical Devices industry
What country is Edwards Lifesciences from?
Edwards Lifesciences is headquartered in United States
When did Edwards Lifesciences go public?
Edwards Lifesciences initial public offering (IPO) was on 27 March 2000
What is Edwards Lifesciences website?
https://www.edwards.com
Is Edwards Lifesciences in the S&P 500?
Yes, Edwards Lifesciences is included in the S&P 500 index
Is Edwards Lifesciences in the NASDAQ 100?
No, Edwards Lifesciences is not included in the NASDAQ 100 index
Is Edwards Lifesciences in the Dow Jones?
No, Edwards Lifesciences is not included in the Dow Jones index
When was Edwards Lifesciences the previous earnings report?
No data
When does Edwards Lifesciences earnings report?
The next expected earnings date for Edwards Lifesciences is 06 February 2025